Media
[NEWS]Hua Medicine Announces First Prescription of Dorzagliatin Dispensed in Hong Kong, China
This press release outlines the latest corporate developments of Hua Medicine. It is issued for informational purposes to shareholders, investors, analysts and healthcare professionals. Nothing in this release should be construed as investment advice. Where applicable, statements regarding future expectations, pipeline progression or regulatory timelines are forward-looking statements subject to risks and uncertainties. Actual results may differ materially.
August 12, 2026 – Shanghai, Hong Kong SAR, China
Hua Medicine ("the Company", HKEX Stock Code: 2552) announced today that, dorzagliatin (trade name: MYHOMSIS®, 華領片®), the Company’s global first-in-class glucokinase activator (GKA), had its first prescription dispensed in Hong Kong. Approved for marketing under Hong Kong’s "1+" innovative drug registration mechanism in February 2026, dorzagliatin has now made a significant breakthrough from regulatory clearance to real-world clinical use.
Beili Cao, Vice President of the Department of Corporate Operations and Great Bay Development of Hua Medicine, said: "The first prescription of dorzagliatin in Hong Kong is a significant milestone, establishing it as the first innovative chronic metabolic disease drug approved and clinically launched under Hong Kong’s '1+' innovative drug mechanism. This achievement underscores our commitment to providing access to innovative treatments broadly across the Greater Bay Area."
Dr. Li Chen, Founder and CEO of Hua Medicine, stated: "We are delighted to see dorzagliatin receive its first prescription in Hong Kong, which fully demonstrates the global clinical competitiveness of China’s independently developed first-in-class therapeutics. Hong Kong boasts a mature community diabetes care framework. As a vital hub connecting China with Southeast Asia and linking to global pharmaceutical markets, Hong Kong features an international regulatory framework, comprehensive medical resources and a sophisticated capital market, making it a core pivot for Hua Medicine’s internationalization strategy."
Capitalizing on Hong Kong’s unique geographical and industrial strengths, Hua Medicine will further advance its commercialization strategy targeting Southeast Asia and global markets. Going forward, the Company will take Hong Kong’s clinical rollout as a benchmark to refine overseas registration and commercial operation networks, steadily advance preparations for dorzagliatin’s launch across the Asia-Pacific region, and continuously export full-cycle innovative diabetes management solutions originating from China.
About Hua Medicine
Hua Medicine (the “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Drawing on global resources, Hua Medicine partners with high-calibre talent worldwide to develop breakthrough technologies and products that advance innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (华堂宁® ) (dorzagliatin tablets) targets the glucose sensor glucokinase, restores glucose sensitivity in patients with type 2 diabetes (T2D), and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30, 2022. It can be used alone or in combination with metformin for adult patients with T2D. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral glucose-lowering drug that can be used in patients with T2D with renal function impairment.
In February 2026, dorzagliatin (trade name: MYHOMSIS®, 華領片®) was approved for marketing by the Pharmaceutical Service of the Department of Health of the Government of the Hong Kong Special Administrative Region of the People's Republic of China.
In June 2026, dorzagliatin (trade name: MYHOMSIS®, 華領片®) was approved for marketing by the Pharmaceutical Administration Bureau of the Macao Special Administrative Region of the People's Republic of China.
Based on the International Diabetes Federation’s 2025 Diabetes Atlas – 11th Edition, there are approximately 148 million diabetic patients in China, 706,000 diabetic patients in Hong Kong SAR, and 52,000 diabetic patients in Macao SAR as of 2024.
For more information
Hua Medicine
Website: www.huamedicine.com
Investors
Email: ir@huamedicine.com
Media
Email: pr@huamedicine.com
Disclaimer
Nothing in this content constitutes a recommendation, promotion, or medical advice regarding any pharmaceutical product. References to efficacy, safety, or therapeutic potential relate strictly to data presented at the meeting and do not imply regulatory approval for any unapproved indications.
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
